ADX10059: Phase IIb data

In the double-blind, placebo-controlled, European Phase IIb ADX10059-204 trial in 103 GERD patients who respond to proton pump inhibitors (PPIs), 120 mg twice-daily ADX10059 monotherapy met the primary endpoint of significantly increasing the number of symptom-free days vs. placebo. Specifically, ADX10059 increased the number of symptom-free days from 0.46 days/week at baseline to 2.5 days/week during the second week of treatment compared with an increase from 0.72 to 1.71 days/week for placebo (p=0.0452). ...